ROS1 fusions in resected stage I-III adenocarcinoma: Results from the European Thoracic Oncology Platform Lungscape project.

Ernst-Jan M SpeelUrania DafniErik ThunnissenJan Hendrik RüschoffCathal O'BrienJacek KowalskiKeith M KerrLukas BubendorfIrene SansanoLeena JosephMark KriegsmannAtilio NavarroKim MonkhorstLine Bille MadsenJavier Hernandez LosaWojciech BiernatAlbrecht StenzingerAndrea RülandLisa M HillenNesa MartiMiguel A Molina-VilaTereza DellaportaRoswitha KammlerSolange PetersRolf A StahelStephen P FinnTeodora Radonicnull null

Published in: Lung cancer (Amsterdam, Netherlands) (2024)

The prevalence of ROS1 fusion in an LUAD stage I-III European cohort was relatively low. ROS1 IHC using SP384 clone is useful for exclusion of ROS1 gene fusion negative cases.

Keyphrases

cell death
dna damage
reactive oxygen species
squamous cell carcinoma
palliative care
risk factors
high throughput
quality improvement
copy number
gene expression
genome wide
radiation therapy
dna methylation
transcription factor
rectal cancer
locally advanced